Frontiers in Endocrinology (Feb 2023)

Hormone replacement treatment regimen is associated with a higher risk of hypertensive disorders of pregnancy in women undergoing frozen-thawed embryo transfer

  • Lijuan Fan,
  • Na Li,
  • Xitong Liu,
  • Xiaofang Li,
  • He Cai,
  • Dan Pan,
  • Ting Wang,
  • Wenhao Shi,
  • Pengfei Qu,
  • Juanzi Shi

DOI
https://doi.org/10.3389/fendo.2023.1133978
Journal volume & issue
Vol. 14

Abstract

Read online

IntroductionIn frozen-thawed embryo transfer (FET) cycles, hormone replacement treatment (HRT) was associated with a higher risk of hypertensive disorders of pregnancy (HDP) compared with natural cycles (NC). Multiple pregnancy was a risk factor for HDP and several studies did not conduct subgroup analysis of singleton pregnancy and multiple pregnancy.ObjectiveTo investigate whether HRT regimen could be a risk factor for HDP in women undergoing FET cycles in singleton and twin pregnancies.MethodsA retrospective cohort study at a tertiary hospital, including a total of 9120 women who underwent FET and achieved ongoing pregnancy; 7590 patients underwent HRT-FET and 1530 NC-FET. The main outcome was HDP. HDP were analyzed for singleton and twin pregnancies, respectively.ResultsIn the singleton pregnancy, the risk of HDP in the HRT-FET group was significantly higher than that in the NC-FET group (6.21% vs. 4.09%; P=0.003). After adjusting for female age oocyte pick up, female age at FET and body mass index (BMI), HRT was found as a risk factor for HDP (adjusted odds ration [aOR]: 1.43; 95% confidence interval [CI]: 1.07 to 1.91; P=0.017). In the multiple pregnancy, the risk of HDP in the HRT-FET and NC-FET groups was similar.ConclusionHRT was associated with a higher risk of HDP in women who underwent FET and achieved singleton pregnancy.

Keywords